


## L-Methionine-d<sub>3</sub>

<b>Cat. No.:</b>	HY-N0326S7		
<b>CAS No.:</b>	13010-53-2		
<b>Molecular Formula:</b>	C <sub>5</sub> H <sub>8</sub> D <sub>3</sub> NO <sub>2</sub> S		
<b>Molecular Weight:</b>	152.23		
<b>Target:</b>	Endogenous Metabolite		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 20 mg/mL (131.38 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	6.5690 mL	32.8450 mL	65.6901 mL
	5 mM	1.3138 mL	6.5690 mL	13.1380 mL
	10 mM	0.6569 mL	3.2845 mL	6.5690 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

L-Methionine-d<sub>3</sub> is the deuterium labeled L-Methionine. L-Methionine is the L-isomer of Methionine, an essential amino acid for human development. Methionine acts as a hepatoprotectant.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA